RUNX3 and neoplasm: Patients with increased/preserved SMAD4 and RUNX3 expression in either the tumor epithelium (HR = 0.34, 95% CI 0.18–0.66, p = 0.001) or the stromal compartment (HR = 0.34, 95% CI 0.2–0.57, p < 0.001) had significantly better prognoses compared to those with decreased/lost expression.